The Hindu Business Line : Lupin enters exclusive pact with Baxter for ceftriaxone injection

The company has entered into an exclusive agreement with the US-based medical products company, Baxter Healthcare Corporation, to distribute the latter's generic version of ceftriaxone sterile vials for injection, in the US market.

Roche is the original patent holder and its product is marketed under the Rocephin brand name. Lupin said that the once-a-day dosing ceftriaxone injection is used to treat infections of the urinary tract, lower respiratory tract, meningitis, skin and skin structure, among others. Interestingly, the company's announcement followed a "premature leak" of the information, possibly as a result of computer-hacking..

Earlier this fiscal, Lupin had received the US Food and Drug Administration approval for its Abbreviated New Drug Application for ceftriaxone vials for injection 250 mg, 500 mg, 1g and 2g. The product would be manufactured at Lupin's plant in Mandideep, Madhya Pradesh — but the launch in the US would happen only after Roche's product patent expires in July 2005.

More Stories on : Announcements | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
ONGC's Seven Seas starts KG basin drilling

Shortage of coking coal — DPL plans to curtail production by 15 pc

Lupin enters exclusive pact with Baxter for ceftriaxone injection

Unichem Labs gets shareholders' nod for share-split, bonus

Preferential offers gain momentum

Ashok Leyland to spend Rs 650 cr on capacity expansion

Setback for Dr Reddy's as Pfizer wins ruling

Berger Intl income up 26.9 pc

Unclaimed fixed deposits — Companies favour quarterly transfer to Fund

Mascon okays rights issue

GM eyes higher market share for Optra

Multivac to earn Rs 60 cr from battery-operated vehicles